Cargando…
Severe bullous drug reaction after COVID‐19 mRNA vaccination
Autores principales: | Irmer, Marie Luise, Nast, Alexander, Ghoreschi, Franziska, Vogt, Annika, Ghoreschi, Kamran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874624/ https://www.ncbi.nlm.nih.gov/pubmed/36259242 http://dx.doi.org/10.1111/ddg.14867 |
Ejemplares similares
-
219 Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid
por: Fernández, A. Mesas, et al.
Publicado: (2023) -
Seven- and 23-year-old Siblings with Papulonodular Lesions after Sun Exposure: A Quiz
por: NERI, Davide, et al.
Publicado: (2021) -
Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
por: Solimani, Farzan, et al.
Publicado: (2021) -
Update on the treatment of psoriasis and psoriatic arthritis – role of apremilast
por: Forchhammer, Stephan, et al.
Publicado: (2015) -
The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy
por: Kokolakis, Georgios, et al.
Publicado: (2022)